HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT

被引：0
|
作者：
Goulis, I. [1 ]
Akriviadis, E. [1 ]
Karatapanis, S. [2 ]
Deutsch, M. [3 ]
Dalekos, G. [4 ]
Raptopoulou-Gigi, M. [5 ]
Drakoulis, C. [6 ]
Bakalos, G. [7 ]
Papatheodoridis, G. [3 ]
机构：
[1] Aristotle Univ Thessaloniki, Sch Med, Hippokrat Gen Hosp, Dept Internal Med 4, GR-54006 Thessaloniki, Greece
[2] Gen Hosp Rhodes, Dept Internal Med 1, Rhodes, Greece
[3] Univ Athens, Sch Med, Hippokrat Hosp, Dept Internal Med 2, GR-11527 Athens, Greece
[4] Univ Thessaly, Sch Med, Larisa, Greece
[5] Aristotle Univ Thessaloniki, Sch Med, Hippokrat Hosp, Dept Internal Med 2, GR-54006 Thessaloniki, Greece
[6] Gen Hosp Nikaia, Dept Internal Med 2, Nikaia, Greece
[7] Roche Hellas, Athens, Greece
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)60716-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
714
引用
收藏
页码：S286 / S287
页数：2
相关论文
共 50 条
  • [11] Predictors of histologic improvement and relationship between sustained response and histology in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®)
    Lau, GK
    Cooksley, G
    Marcellin, P
    Piratvisuth, T
    Hadziyannis, S
    Farci, P
    Fried, MW
    Bonino, F
    Jin, R
    Button, P
    Popescu, M
    HEPATOLOGY, 2005, 42 (04) : 587A - 587A
  • [12] On treatment prediction of post-treatment sustained response to Peginterferon alfa-2a for HBeAg-negative Chronic Hepatitis B (CHB) patients using HBsAg and HBV DNA levels at weeks 12 and 24: PERSEAS cohort final results
    Goulis, Ioannis
    Karatapanis, Stylianos
    Akriviadis, Evangelos A.
    Deutsch, Melanie
    Dalekos, George N.
    Raptopoulou-Gigi, Maria
    Mimidis, Konstantinos
    Germanidis, Georgios
    Triantos, Christos K.
    Drakoulis, Christos
    Chounta, Athina
    Vafiadis, Irene
    Hatzis, Grigorios
    Gagalis, Asterios
    Vlachogiannakos, Jiannis
    Zintzaras, Elias
    Koulouris, Sokratis
    Bakalos, George
    Papatheodoridis, George V.
    HEPATOLOGY, 2013, 58 : 697A - 698A
  • [13] Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype
    Brunetto, Maurizia R.
    Marcellin, Patrick
    Cherubini, Beatrice
    Yurdaydin, Cihan
    Farci, Patrizia
    Hadziyannis, Stephanos J.
    Rothe, Vivien
    Regep, Loredana
    Bonino, Ferruccio
    JOURNAL OF HEPATOLOGY, 2013, 59 (06) : 1153 - 1159
  • [14] Role of baseline and on-treatment quantitative HBeAg in predicting response to peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy in chronic hepatitis B
    Fried, Michael W.
    Lau, George K. K.
    Liaw, Yun-Fan
    Luo, Kang-Xian
    Piratvisuth, Teerha
    Cooksley, Graham
    Marcellin, Patrick
    Thongsawat, Satawat
    Button, Peter
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A72 - A72
  • [15] Peginterferion alfa-2a (40KD) (Pegasys®) for the treatment of patients with chronic hepatitis C
    Ferenci, P
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2003, 57 (07) : 610 - 615
  • [16] PEGINTERFERON ALFA-2A [40KD] PLUS ADEFOVIR FOR 96 WEEKS IN HBEAG-NEGATIVE CHB RESULTS IN HIGH RATES OF HBSAG CLEARANCE/SEROCONVERSION
    Cao, Z.
    Yu, H.
    Ma, L.
    Zhang, Y.
    Liu, Y.
    Ma, B.
    Wu, H.
    Chen, X.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S283 - S283
  • [17] Efficacy and Safety of Peginterferon alfa-2a (40KD) in HBeAg-positive Chronic Hepatitis B Patients
    Caruntu, Florin Alexandru
    Streinu-Cercel, Adrian
    Gheorghe, Liliana Simona
    Grigorescu, Mircea
    Sporea, Ioan
    Stanciu, Carol
    Andronescu, Dan
    Voinea, Florea
    Diculescu, Mircea
    Oproiu, Alexandru
    Voiosu, Rodu
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2009, 18 (04) : 425 - 431
  • [18] Predicting response to peginterferon alfa-2a (40 KD) (PEGASYS®) in Asian patients with HBeAg-positive chronic hepatitis B
    Cooksley, Graham
    Chow, Wan Cheng
    Piratvisuth, Teerha
    Lau, George K. K.
    Mccloud, Philip
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A108 - A108
  • [19] Peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin is an efficacious and safe treatment for chronic hepatitis C in patients with cirrhosis.
    Marcellin, P
    Brillanti, S
    Cheínquer, H
    Cooksley, WGE
    Shiffmann, ML
    Schmidt, WE
    Brunda, M
    HEPATOLOGY, 2002, 36 (04) : 576A - 576A
  • [20] Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B
    Piratvisuth, Teerha
    Lau, George
    Chao, You-Chen
    Jin, Rui
    Chutaputti, Anuchit
    Zhang, Q. -B.
    Tanwandee, Tawesak
    Button, Peter
    Popescu, Matei
    HEPATOLOGY INTERNATIONAL, 2008, 2 (01) : 102 - 110
12345